PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database

PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database

BackgroundTransplant recipients face increased cancer mortality due to immunosuppressive treatments. Immune checkpoint inhibitors (ICI) have improved survival rates, but data on the use of these agents in transplant recipients is scarce. ICI may trigger allograft rejection, but the absolute risk of...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexandre O. Gérard, Diane Merino, Jonathan Benzaquen, Alexandre Destere, Delphine Borchiellini, Clément Gosset, Fanny Rocher, Marine Andreani, Charles-Hugo Marquette, Henri Montaudié, Milou-Daniel Drici, Antoine Sicard
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
immune checkpoint inhibitors
allograft rejection
transplantation
pharmacovigilance
oncology
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1514033/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1514033/full

Similar Items